Autolus Q2 Revenue Surges 119% on AUCATZYL Sales; Net Loss Narrows Ahead of Key CARLYSLE Data

• Autolus Therapeutics (AUTL) reported Q2 revenue growth of approximately 119% from commercial AUCATZYL sales while narrowing its net loss
• AUCATZYL, a CAR-T cell therapy for relapsed B-cell non-Hodgkin lymphoma, continues gaining commercial traction with accelerating treatment center adoption
• CARLYSLE trial data expected by year-end represents a potential major catalyst that could significantly expand AUTL's addressable market

Autolus Therapeutics delivered a strong second quarter with commercial-stage AUCATZYL generating approximately 119% year-over-year revenue growth, demonstrating accelerating adoption of its CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The company has successfully transitioned from a development-stage biotech to a revenue-generating commercial entity, with AUCATZYL gaining traction across academic medical centers and specialized oncology centers managing complex hematologic malignancies. The narrowing net loss reflects the operating leverage inherent in the commercial ramp: while sales force and manufacturing infrastructure was built upfront, each additional unit sold carries meaningfully higher gross margins as fixed cost absorption improves.

AUCATZYL competes in the rapidly growing CAR-T therapy market alongside Kymriah, Yescarta, and Breyanzi. Autolus has differentiated its product through a distinct T cell manufacturing platform called FAST CAR, which claims to produce fresher, less exhausted T cells compared to some competitors. This manufacturing differentiation, if it translates to real-world clinical outcomes differences, could become a key commercial differentiator as physicians gain experience with the product. The company's U.S. commercial infrastructure has been ramped appropriately for the current market opportunity, and international expansion approvals could provide incremental growth vectors beyond the current U.S.-focused trajectory driving results.

The CARLYSLE trial data, expected by year-end, represents Autolus' most significant near-term catalyst. This study is evaluating AUCATZYL or a related construct in a different oncology indication, potentially expanding the company's total addressable market well beyond the current B-cell lymphoma approval. Positive data could trigger a meaningful stock re-rating as investors price in a significantly larger opportunity. Risk factors include commercial execution challenges inherent to CAR-T therapies—manufacturing complexity, hospital logistics, and patient identification—and the binary nature of the CARLYSLE data readout. The 119% revenue growth pace is unlikely to be sustained indefinitely, but the trajectory supports continued progress toward cash-flow breakeven.